Skip to main content

Advanced Search

Haematologica
  • Home
  • Current Issue
  • Ahead Of Print
  • Archive
  • Submit a Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Submit a Manuscript
    • Track a Manuscript
  • About Us
    • About Haematologica
    • Editorial Board
    • Our Policies
  • More
    • Advertising
    • Rights & Permissions
    • Alerts
    • Feedback
    • Contact
Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups
S Amadori, S Suciu, R Willemze, F Mandelli, D Selleslag, R Stauder, A Ho, C Denzlinger, G Leone, P Fabris, P Muus, M Vignetti, A Hagemeijer, F Beeldens, O Anak, T De Witte
Haematologica January 2004 89: 950-956; doi:
S Amadori
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Suciu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Willemze
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F Mandelli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D Selleslag
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Stauder
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Ho
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C Denzlinger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G Leone
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P Fabris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P Muus
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Vignetti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Hagemeijer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F Beeldens
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O Anak
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T De Witte
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site

Author Affiliations

  1. S Amadori,
  2. S Suciu,
  3. R Willemze,
  4. F Mandelli,
  5. D Selleslag,
  6. R Stauder,
  7. A Ho,
  8. C Denzlinger,
  9. G Leone,
  10. P Fabris,
  11. P Muus,
  12. M Vignetti,
  13. A Hagemeijer,
  14. F Beeldens,
  15. O Anak,
  16. T De Witte,
  17. EORTC leukemia group and
  18. GIMEMA leukemia group
  1. Department of Hematology, University Tor Vergata, St. Eugenio Hospital, Rome, Italy. mc7673@mclink.it
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

BACKGROUND AND OBJECTIVES: Acute myeloid leukemia (AML) in the elderly is associated with low rates of response to conventional chemotherapy and long-term survival, highlighting the need for innovative treatment strategies. Gemtuzumab ozogamicin (GO) is an immunoconjugate that has shown activity in relapsed AML with a favorable safety profile. The aim of this collaborative trial was to assess the feasibility, safety, and antileukemic activity of administering GO followed by conventional chemotherapy as first line therapy in patients aged 61-75 years with AML. DESIGN AND METHODS: Eligible patients received frontline treatment with GO 9 mg/m2 infused intravenously on days 1 and 15. Following response assessment to GO, patients were started on conventional chemotherapy consisting of the MICE regimen (mitoxantrone, cytarabine, etoposide). No further treatment was planned for complete responders. RESULTS: Among the 57 evaluable patients, 38 (67%) completed the entire sequential treatment as planned. The overall response rate to the entire induction sequence was 54.4% (31/57), with complete remission (CR) in 35.1% and complete remission with incomplete platelet recovery (CRp) in 19.3%. Rates of failure due to treatment-related mortality or resistant disease were 14.1% (3 toxic deaths during the GO segment, 5 during MICE) and 29.9%, respectively. An initial response to GO was documented in 20 patients (35.1%), with CR in 22.8% and CRp in 12.3%; 6 additional patients entered a partial remission. Reversible myelosuppression and liver toxicity were the main adverse events during both segments of induction. Frontline GO was associated with modest mucosal and gastrointestinal toxicity, but grade 3-4 pancytopenia was universal and prolonged. Hepatic veno-occlusive disease developed in 3 patients after GO and 2 after MICE, resulting in 4 deaths from liver failure. One-year survival at follow-up was 34%. Twelve patients continue in CR/CRp after a median of 226 days. INTERPRETATION AND CONCLUSIONS: The sequential combination of GO and conventional chemotherapy is a feasible and active treatment strategy for older patients with untreated AML. This novel regimen is now being compared in a phase III trial (AML-17).

PreviousNext
Back to top

Vol 89 Issue 8

Haematologica: 89 (8)
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Email

Thank you for your interest in spreading the word about Haematologica.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups
(Your Name) has forwarded a page to you from Haematologica
(Your Name) thought you would like to see this page from the Haematologica web site.
Citation Tools
Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups
S Amadori, S Suciu, R Willemze, F Mandelli, D Selleslag, R Stauder, A Ho, C Denzlinger, G Leone, P Fabris, P Muus, M Vignetti, A Hagemeijer, F Beeldens, O Anak, T De Witte, EORTC leukemia group, GIMEMA leukemia group
Haematologica Jan 2004, 89 (8) 950-956;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
S Amadori, S Suciu, R Willemze, F Mandelli, D Selleslag, R Stauder, A Ho, C Denzlinger, G Leone, P Fabris, P Muus, M Vignetti, A Hagemeijer, F Beeldens, O Anak, T De Witte, EORTC leukemia group, GIMEMA leukemia group
Haematologica Jan 2004, 89 (8) 950-956;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Alert me when this article is cited
  • Alert me if a correction is posted

Jump To

  • Article
  • Info & Metrics
  • PDF

More in this TOC Section

  • Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma
  • Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study
  • Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major
Show more Clinical Trial, Phase II

Related Articles

Cited By...

What about you?
Tell us your interests and get all the new contents of Haematologica in advance

 

 

Navigate

  • Home
  • Current issue
  • Ahead of print
  • Archive
  • Info for
    • Authors
    • Reviewers
    • Advertisers
    • Subscribers
  • About us
    • About Haematologica
    • Editorial Board
    • Our policies

For Authors

  • Author guidelines
  • Submit Manuscript
  • Track Manuscript

For Reviewers

  • Reviewer Guidelines
  • Access Your Profile
  • Access Your Tasks
  • 2014 reviewers

For Advertisers

  • Information For Advertising

Education

  • Review Articles
  • Guideline Articles

More

  • Rights & Permissions
  • Advertising
  • Alerts
  • Feedback
  • Contact
  • App

Copyright © 2019 by the Ferrata Storti Foundation

ISSN 0390-6078 print

ISSN 1592-8721 online